CDT Equity Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
2.460
-0.030 (-1.20%)
At close: Apr 28, 2026, 4:00 PM EDT
2.400
-0.060 (-2.44%)
After-hours: Apr 28, 2026, 4:16 PM EDT
CDT Equity Employees
CDT Equity had 4 employees as of December 31, 2025. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$9,806,000
Market Cap
11.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% |
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| IN8bio | 17 |
| Soligenix | 14 |
| Cellectar Biosciences | 11 |
| Intensity Therapeutics | 7 |
| Traws Pharma | 7 |
| Phio Pharmaceuticals | 6 |
CDT News
- 12 days ago - CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery - GlobeNewsWire
- 15 days ago - What's Going On With CDT Equity Shares On Monday? - Benzinga
- 21 days ago - CDT Notes Sarborg Publication of PRISM Framework Expanding AI - GlobeNewsWire
- 4 weeks ago - CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings - GlobeNewsWire
- 4 weeks ago - CDT Equity Inc. Announces Reverse Stock Split - GlobeNewsWire
- 5 weeks ago - CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy - GlobeNewsWire
- 5 weeks ago - CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth - GlobeNewsWire
- 6 weeks ago - CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence - GlobeNewsWire